A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colony stimulating factor support, as first-line therapy for hormone-refractory metastatic brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachelot, T, Gomez, F, Biron, P, Ray-Coquard, I, Soler-Michel, P, Philip, I, Guastalla, J P, Rebattu, P, Dumortier, A, Droz, J P, Blay, J Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376188/
https://www.ncbi.nlm.nih.gov/pubmed/12402145
http://dx.doi.org/10.1038/sj.bjc.6600631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376188/
https://www.ncbi.nlm.nih.gov/pubmed/12402145
http://dx.doi.org/10.1038/sj.bjc.6600631

Ejemplares similares